BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors July 19, 2023
F-star Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies July 12, 2023
Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor Brain Mets Harboring PI3K Pathway Mutations In Combination With Radiation Therapy July 11, 2023
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® and Novel ADC Candidates for Advanced Solid Tumors in China July 5, 2023
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for R/R Advanced Solid Tumors July 5, 2023
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders June 21, 2023
Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours June 14, 2023
Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field May 31, 2023
KSQ Therapeutics And Takeda Expand Strategic Immuno-Oncology Collaboration To Identify And Validate Novel Tumor Targets May 31, 2023
Gilead Strengthens Early Pipeline In Oncology And Inflammation Through The Acquisition Of XinThera May 18, 2023
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology May 18, 2023
Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement May 18, 2023
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Gen ADC Program in Oncology May 10, 2023
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics May 10, 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors May 10, 2023
First Patient Dosed in Ph 1/2 Trial of STX-478 for the Treatment of Breast Cancer and Other Solid Tumors May 10, 2023
Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME announced May 10, 2023
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients April 27, 2023
CTRL Therapeutics Launches with $10M Seed Financing to Advance Next-Gen Cell Therapy Platform for the Treatment of Solid Tumors April 20, 2023
